Analystreport

LogicBio Therapeutics, Inc. (NASDAQ: LOGC) had its "buy" rating re-affirmed by analysts at William Blair.

LogicBio Therapeutics, Inc.  (LOGC) 
Last logicbio therapeutics, inc. earnings: 8/13 08:00 am Check Earnings Report